Roivant Sciences (ROIV)
Health Care
A biopharmaceutical company developing a diversified pipeline of immunology and inflammatory disease therapeutics through nimble, incentivized subsidiary companies called "Vants."
What Roivant Sciences does
Roivant is a biopharmaceutical company that develops and commercializes medicines to treat patients with autoimmune, inflammatory, and rare diseases. The company operates through a distinctive "Vant model," creating nimble subsidiary companies (such as Priovant, Immunovant, and Pulmovant) that function as independent biotech firms with their own management teams and equity incentives. Roivant in-licenses or acquires promising drug candidates and deploys them through these Vants, while maintaining centralized capital allocation and applying proprietary computational and technology platforms to accelerate development. Beyond therapeutics, Roivant incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business.
Themes: ["JAK/TYK2 inhibition / dermatomyositis","FcRn-targeting antibodies / autoimmune diseases","Rare inflammatory diseases","Pulmonary hypertension / interstitial lung disease","Clinical-stage biopharmaceutical development","Distributed biotech subsidiaries (\"Vant model\")","LNP / gene therapy platform"]
Fundamentals
- Price$36.81 as of 2026-07-09 close
- Market cap$26.5B as of 2026-07-10
- 1-year return+228.1% as of 2026-07-09 close
- Net margin-3629.2% as of 2026-07-10
- Gross margin+84.4% as of 2026-07-10
- ROE-6.9% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Revenue growth (YoY)-89.2% as of 2026-07-10
- Revenue CAGR (3y)-36.0% SEC XBRL
- Beta1.11 as of 2026-07-10
Key risks (from latest filing)
["Regulatory approval risk: Brepocitinib for dermatomyositis has a PDUFA date of 3Q 2026, and multiple pipeline programs remain in Phase 2/3 trials with inherent clinical and regulatory uncertainty; failure to obtain FDA approval or meet clinical endpoints would severely impact the company's near-term catalysts and valuation.","Intellectual property and litigation risk: Genevant's LNP platform is subject to ongoing U.S. litigation with Moderna (jury trial in March 2026) and multiple ex-U.S. cases, with potential for adverse judgments that could restrict or invalidate key IP or require significant payments.","Concentrated pipeline risk and financing risk: With highly negative margins (-3629.19%) and declining revenue (-89.16% YoY), the company is unprofitable and dependent on continued capital access to fund early-stage clinical programs across multiple therapeutic areas; delays, failures, or significant capital market disruptions could impair funding availability."]
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.